What are the key takeaways from this Beyond Biotech episode?

Key insights include: **PROTAC catalytic mechanism:** Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.; **Capital allocation framework for platform companies:** Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets.; **Blood-brain barrier penetration via medicinal chemistry:** ARV-102, Arvinas's oral LRRK2 degrader targeting Parkinson's disease and progressive supranuclear palsy, crosses the blood-brain barrier through optimized molecular design alone, without active transporters or delivery vehicles. Phase 1 data confirmed CNS penetration, with next-phase trials planned before year-end 2026.

What did Randy Teal discuss on Beyond Biotech?

Arvinas CEO Randy Teal joins Beyond Biotech to discuss the FDA approval of vepdegestrant, the first PROTAC protein degrader to complete Phase 3 trials, explaining how the technology eliminates disease-causing proteins entirely rather than blocking them, and outlining the company's pipeline across oncology and neurodegenerative diseases. Key topics include: **PROTAC catalytic mechanism:** Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.; **Capital allocation framework for platform companies:** Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets..

How long is this episode of Beyond Biotech?

This episode is 35 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Beyond Biotech

The first PROTAC is here. What comes next in protein degradation?

July 3, 2026

35 min episode · 2 min read

Randy Teal

Episode

35 min

Read time

2 min

Topics

Productivity, Relationships, Investing

AI-Generated Summary

Published Jul 3, 2026

Key Takeaways

✓PROTAC catalytic mechanism: Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.
✓Capital allocation framework for platform companies: Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets.
✓Blood-brain barrier penetration via medicinal chemistry: ARV-102, Arvinas's oral LRRK2 degrader targeting Parkinson's disease and progressive supranuclear palsy, crosses the blood-brain barrier through optimized molecular design alone, without active transporters or delivery vehicles. Phase 1 data confirmed CNS penetration, with next-phase trials planned before year-end 2026.
✓Pipeline readout timeline for 2026–2027: Multiple Arvinas programs reach first Phase 1 data within 12–18 months: BCL6 degrader for non-Hodgkin's lymphoma reads out late 2026; SBMA/Kennedy's disease degrader reports first-half 2027; HPK1 immuno-oncology trial starts Q3 2026. These simultaneous readouts will directly drive partnering, financing, and internal investment decisions.
✓Partnering strategy timing: Arvinas maintained ongoing briefings with Novartis on its androgen receptor degrader program for several years before finalizing the 2024 partnership. This signals that biotech companies should begin cultivating large pharma relationships at early clinical stages, not at Phase 2 completion, as deal timelines routinely span multiple years of relationship-building.

What It Covers

Arvinas CEO Randy Teal joins Beyond Biotech to discuss the FDA approval of vepdegestrant, the first PROTAC protein degrader to complete Phase 3 trials, explaining how the technology eliminates disease-causing proteins entirely rather than blocking them, and outlining the company's pipeline across oncology and neurodegenerative diseases.

Key Questions Answered

•PROTAC catalytic mechanism: Unlike traditional small molecules requiring a one-to-one drug-to-protein ratio, PROTACs recruit the cell's natural degradation machinery, then detach and repeat the process. This catalytic recycling means lower drug quantities can eliminate larger protein volumes, making PROTACs particularly effective against resistance mechanisms where tumors amplify protein production.
•Capital allocation framework for platform companies: Arvinas uses a three-way triangulation when deciding which programs to advance internally versus partner: what the company can fund, what large pharma partners want to invest in, and what biotech investors will finance. Programs misaligned with investor timelines become partnership candidates, preserving internal capital for high-priority assets.
•Blood-brain barrier penetration via medicinal chemistry: ARV-102, Arvinas's oral LRRK2 degrader targeting Parkinson's disease and progressive supranuclear palsy, crosses the blood-brain barrier through optimized molecular design alone, without active transporters or delivery vehicles. Phase 1 data confirmed CNS penetration, with next-phase trials planned before year-end 2026.
•Pipeline readout timeline for 2026–2027: Multiple Arvinas programs reach first Phase 1 data within 12–18 months: BCL6 degrader for non-Hodgkin's lymphoma reads out late 2026; SBMA/Kennedy's disease degrader reports first-half 2027; HPK1 immuno-oncology trial starts Q3 2026. These simultaneous readouts will directly drive partnering, financing, and internal investment decisions.
•Partnering strategy timing: Arvinas maintained ongoing briefings with Novartis on its androgen receptor degrader program for several years before finalizing the 2024 partnership. This signals that biotech companies should begin cultivating large pharma relationships at early clinical stages, not at Phase 2 completion, as deal timelines routinely span multiple years of relationship-building.

Notable Moment

Teal describes Kennedy's disease patients as having zero options to slow disease progression across decades of decline, positioning Arvinas's SBMA PROTAC program — which entered the clinic in 2026 — as potentially the first therapy capable of modifying the disease course through targeted protein degradation.

Know someone who'd find this useful?

Episode Transcript

Hello, and welcome to Beyond Biotech, the weekly podcast from Labiontech. I'm Dylan Kossain, and this is episode 204 for the podcast. Today, I'm sitting down with Randy Teal, president and CEO of Arvanus, a clinical stage biotech based in New Haven, Connecticut that's doing something genuinely new in medicine. Arvanus is pioneering a technology called PROTAC protein degradation. They've got a platform that doesn't just block disease causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milestone. The first protect ever to succeed in a phase three clinical trial with a regulatory filing now in front of the FDA. Randy was appointed CEO earlier this year, bringing over twenty years of biopharma experience and a deep strategic understanding to the company he's helped to develop since 2018. This is a conversation about bold science, smart leadership, and what comes next. Let's get into it. Randy, welcome to Beyond Biotech. Thank you, Dylan. It's great to be here this morning. You've been with, Arvanus since 2018. You were there for the IPO. You led the strategy, the business development. Now you're the CEO. Before we get too much into the business and science of what you're doing there, maybe you can just start by introducing yourself. Tell me a little bit about how you got yourself to where you are. Well, it it's a long and winding road, Dylan. And I I think anybody who tells you that they had it all planned out at the start is probably is probably fibbing a bit. So if if I go way back, I started my career in the lab actually as a graduate student in immunology. Did that, got a PhD, and then very rapidly realized that, that my place, of excellence was less so in the lab and looked for opportunities to be quite clear that didn't require me to do a postdoc. And about that time, I got interested in management consulting largely because they would come to recruit at the universities. And so I joined a management consultancy for seven years, before jumping sort of back to the science side, back to biotech. And I think that dual history sort of both as a as a PhD scientist as well as squarely on the business side working for McKinsey, I think gives me a pretty balanced, view of how to look at biotech. And I think that's carried me pretty well through my my subsequent endeavors. I went to Alexion first, was was there for three years, ended up as head of strategy, and then moved over to our Venice back in 2018. And as you pointed out, at that point, it was a private company. It was a preclinical company. It's a platform company, something I'm sure we'll get into over the over the course of this discussion. And started off at Arvinis in …

Get the full transcript (6,806 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Beyond Biotech transcripts →